Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ZT 031

Drug Profile

ZT 031

Alternative Names: cPTH (1-31); Cyclic hPTH-(1-31)-NH2 injection; Ostabolin injection; Ostabolin-C injectable; Ostabolin-C injection; Ostabolin-C injection - Azelon Pharmaceuticals; Parathyroid hormone analogue injection - Azelon Pharmaceuticals

Latest Information Update: 04 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zelos Therapeutics Inc
  • Developer Azelon Pharmaceuticals
  • Class Osteoporosis therapies; Peptide fragments; Peptide hormones
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Osteodystrophy; Osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 15 Dec 2011 No development reported - Phase-I for Osteodystrophy in Canada (SC)
  • 15 Dec 2011 No development reported - Phase-II for Postmenopausal osteoporosis in Canada (SC)
  • 15 Dec 2011 No development reported - Preclinical for Osteoporosis in Canada (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top